JP2009507011A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009507011A5 JP2009507011A5 JP2008528601A JP2008528601A JP2009507011A5 JP 2009507011 A5 JP2009507011 A5 JP 2009507011A5 JP 2008528601 A JP2008528601 A JP 2008528601A JP 2008528601 A JP2008528601 A JP 2008528601A JP 2009507011 A5 JP2009507011 A5 JP 2009507011A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolidine
- carbonitrile
- alkyl
- methoxybenzoylamino
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- ALSCEGDXFJIYES-UHFFFAOYSA-N pyrrolidine-2-carbonitrile Chemical compound N#CC1CCCN1 ALSCEGDXFJIYES-UHFFFAOYSA-N 0.000 claims 37
- 150000001875 compounds Chemical class 0.000 claims 32
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 15
- 125000003118 aryl group Chemical group 0.000 claims 15
- 125000001072 heteroaryl group Chemical group 0.000 claims 11
- 125000003342 alkenyl group Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 229910052717 sulfur Inorganic materials 0.000 claims 5
- 150000007649 L alpha amino acids Chemical class 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 230000007882 cirrhosis Effects 0.000 claims 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims 3
- RGICCULPCWNRAB-UHFFFAOYSA-N 2-[2-(2-hexoxyethoxy)ethoxy]ethanol Chemical compound CCCCCCOCCOCCOCCO RGICCULPCWNRAB-UHFFFAOYSA-N 0.000 claims 2
- 208000016216 Choristoma Diseases 0.000 claims 2
- 206010027476 Metastases Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 210000000601 blood cell Anatomy 0.000 claims 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000004761 fibrosis Effects 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 239000011159 matrix material Substances 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 208000004235 neutropenia Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- VEBQYHFHXCAREJ-UHFFFAOYSA-N pyrrolidin-2-ylboronic acid Chemical compound OB(O)C1CCCN1 VEBQYHFHXCAREJ-UHFFFAOYSA-N 0.000 claims 2
- 238000007634 remodeling Methods 0.000 claims 2
- 230000008467 tissue growth Effects 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- JWFDLILYICVSFH-UHFFFAOYSA-N 1,1-dioxo-1,3-thiazolidine-4-carbonitrile Chemical compound O=S1(=O)CNC(C#N)C1 JWFDLILYICVSFH-UHFFFAOYSA-N 0.000 claims 1
- PRSDPVKGJUBIAA-UHFFFAOYSA-N 1,3-thiazolidine-4-carbonitrile Chemical compound N#CC1CSCN1 PRSDPVKGJUBIAA-UHFFFAOYSA-N 0.000 claims 1
- IMSVLBGSOYXVIQ-UHFFFAOYSA-N 1-oxo-1,3-thiazolidine-4-carbonitrile Chemical compound O=S1CNC(C#N)C1 IMSVLBGSOYXVIQ-UHFFFAOYSA-N 0.000 claims 1
- 239000004475 Arginine Substances 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- -1 NR 4 R 5 Chemical group 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- CPFVGUFLDVAAHL-UHFFFAOYSA-N azetidine-2-carbonitrile Chemical compound N#CC1CCN1 CPFVGUFLDVAAHL-UHFFFAOYSA-N 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- OQXQSKNSVJCHQM-LBPRGKRZSA-N n-[1-[(2s)-2-cyanopyrrolidin-1-yl]-2-methyl-1-oxopropan-2-yl]-2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(=O)NC(C)(C)C(=O)N1[C@H](C#N)CCC1 OQXQSKNSVJCHQM-LBPRGKRZSA-N 0.000 claims 1
- MMEPVYJSHWWBSV-HNNXBMFYSA-N n-[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]-2-methoxy-n-(2-methylpropyl)benzamide Chemical compound COC1=CC=CC=C1C(=O)N(CC(C)C)CC(=O)N1[C@H](C#N)CCC1 MMEPVYJSHWWBSV-HNNXBMFYSA-N 0.000 claims 1
- HSIDTMLTVRFYGR-AWEZNQCLSA-N n-[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]naphthalene-1-carboxamide Chemical compound C=1C=CC2=CC=CC=C2C=1C(=O)NCC(=O)N1CCC[C@H]1C#N HSIDTMLTVRFYGR-AWEZNQCLSA-N 0.000 claims 1
- SPTJGQOVDKLVLF-SFHVURJKSA-N n-benzyl-n-[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]-2-methoxybenzamide Chemical compound COC1=CC=CC=C1C(=O)N(CC=1C=CC=CC=1)CC(=O)N1[C@H](C#N)CCC1 SPTJGQOVDKLVLF-SFHVURJKSA-N 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- YAVXLTMRALFZIS-UHFFFAOYSA-N piperidine-2-carbonitrile Chemical compound N#CC1CCCCN1 YAVXLTMRALFZIS-UHFFFAOYSA-N 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71332405P | 2005-09-02 | 2005-09-02 | |
| EP05108049A EP1760076A1 (en) | 2005-09-02 | 2005-09-02 | FAP Inhibitors |
| PCT/IB2006/003512 WO2007085895A2 (en) | 2005-09-02 | 2006-08-31 | Fap inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009507011A JP2009507011A (ja) | 2009-02-19 |
| JP2009507011A5 true JP2009507011A5 (https=) | 2009-08-20 |
Family
ID=38309561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008528601A Pending JP2009507011A (ja) | 2005-09-02 | 2006-08-31 | Ｆａｐ阻害剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8183280B2 (https=) |
| EP (2) | EP1760076A1 (https=) |
| JP (1) | JP2009507011A (https=) |
| KR (1) | KR20080043383A (https=) |
| AU (1) | AU2006336854A1 (https=) |
| CA (1) | CA2627607A1 (https=) |
| NO (1) | NO20081636L (https=) |
| RU (1) | RU2008112683A (https=) |
| WO (1) | WO2007085895A2 (https=) |
| ZA (1) | ZA200802867B (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| KR101452915B1 (ko) | 2006-05-04 | 2014-10-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 다형태 |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| BRPI0815405A2 (pt) * | 2007-08-17 | 2015-02-03 | Boehringer Ingelheim Int | Compostos derivados de purina, processo para a preparação de uma composição farmacêutica e uso dos mesmos |
| EP2071337A1 (en) * | 2007-12-10 | 2009-06-17 | F.Hoffmann-La Roche Ag | Seprase as a marker for cancer |
| MX2010004671A (es) * | 2007-12-10 | 2010-05-27 | Hoffmann La Roche | Seprasa como marcador para cancer. |
| BRPI0906094B8 (pt) * | 2008-03-05 | 2021-05-25 | National Health Res Inst | composto |
| PE20091730A1 (es) | 2008-04-03 | 2009-12-10 | Boehringer Ingelheim Int | Formulaciones que comprenden un inhibidor de dpp4 |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| CA2736421A1 (en) | 2008-09-10 | 2010-03-18 | Boehringer Ingelheim International Gmbh | Combination therapy for the treatment of diabetes and related conditions |
| WO2010036814A1 (en) * | 2008-09-25 | 2010-04-01 | Molecular Insight Pharmaceuticals, Inc. | Selective seprase inhibitors |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| JP2012512848A (ja) | 2008-12-23 | 2012-06-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 有機化合物の塩の形態 |
| TW201036975A (en) | 2009-01-07 | 2010-10-16 | Boehringer Ingelheim Int | Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy |
| WO2010083570A1 (en) * | 2009-01-23 | 2010-07-29 | The University Of Sydney | Novel metabolic disease therapy |
| KR20240090632A (ko) | 2009-11-27 | 2024-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
| CA3070513C (en) | 2010-05-05 | 2023-01-03 | Boehringer Ingelheim International Gmbh | A dpp-4 inhibitor for use in treatment of skin-alterations or necrosis |
| KR20130093012A (ko) | 2010-06-24 | 2013-08-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 요법 |
| WO2012061408A2 (en) * | 2010-11-02 | 2012-05-10 | Rigel Pharmaceuticals. Inc. | Method for making macrocycles |
| AR083878A1 (es) | 2010-11-15 | 2013-03-27 | Boehringer Ingelheim Int | Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento |
| CA2819810A1 (en) * | 2010-12-06 | 2012-06-14 | The University Of British Columbia | Granzyme b inhibitor compositions, methods and uses for promoting wound healing |
| DK2731947T3 (en) | 2011-07-15 | 2019-04-23 | Boehringer Ingelheim Int | SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES |
| WO2013107820A1 (en) * | 2012-01-17 | 2013-07-25 | Universiteit Antwerpen | Novel fap inhibitors |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| WO2013171166A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis |
| WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| US20150320892A1 (en) * | 2012-06-29 | 2015-11-12 | Ge Healthcare Limited | Imaging fibrosis |
| EA021236B1 (ru) * | 2012-10-03 | 2015-05-29 | Дафот Энтерпраизес Лимитед | Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ |
| EP2730571A1 (en) * | 2012-11-12 | 2014-05-14 | Universitat De Barcelona | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
| EP3110449B1 (en) | 2014-02-28 | 2023-06-28 | Boehringer Ingelheim International GmbH | Medical use of a dpp-4 inhibitor |
| US9682933B2 (en) * | 2014-05-30 | 2017-06-20 | British Columbia Cancer Agency Branch | Androgen receptor modulators and methods for their use |
| EP4233840A3 (en) | 2016-06-10 | 2023-10-18 | Boehringer Ingelheim International GmbH | Combinations of linagliptin and metformin |
| CN116474108A (zh) | 2016-12-14 | 2023-07-25 | 普渡研究基金会 | 成纤维细胞活化蛋白(fap)-靶向成像和治疗 |
| EP3565560B1 (en) | 2017-01-09 | 2024-05-29 | OnkosXcel Therapeutics, LLC | Predictive and diagnostic methods for prostate cancer |
| JP2021506972A (ja) * | 2017-12-15 | 2021-02-22 | プラクシス バイオテック エルエルシー | 線維芽細胞活性化タンパク質の阻害剤 |
| CN113811529A (zh) * | 2018-12-21 | 2021-12-17 | 普拉西斯生物技术有限责任公司 | 成纤维细胞激活蛋白抑制剂 |
| KR102274077B1 (ko) * | 2019-03-29 | 2021-07-09 | 보령제약 주식회사 | Fap 저해제로서의 피롤리딘 유도체 및 이를 포함하는 약학적 조성물 |
| EP4055014B1 (en) | 2019-11-06 | 2025-04-30 | Yuhan Corporation | PYRROLIDINE AND PIPERIDINE COMPOUNDS |
| CN115697413B (zh) * | 2020-03-24 | 2025-08-01 | 塔夫茨大学信托人 | 靶向fap的放射性药物和显像剂以及与之相关的用途 |
| CA3176497A1 (en) | 2020-05-07 | 2021-11-11 | Fatima MECHTA-GRIGORIOU | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| CN116745291A (zh) * | 2020-12-17 | 2023-09-12 | 阿斯利康(瑞典)有限公司 | N-(2-(4-氰基噻唑烷-3-基)-2-氧代乙基)-喹啉-4-甲酰胺 |
| JP2024525589A (ja) | 2021-07-09 | 2024-07-12 | アリゴス セラピューティクス インコーポレイテッド | 抗ウイルス化合物 |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| WO2023247488A1 (en) * | 2022-06-21 | 2023-12-28 | Astrazeneca Ab | N-(2-(3-cyano-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| CA3260370A1 (en) * | 2022-06-21 | 2023-12-28 | Astrazeneca Ab | SOLID FORMS OF N-(2-(4-CYANOTHIAZOLIDIN-3-YL)-2-OXOEETHYL)-6-MORPHOLINOQUINOLEIN-4-CARBOXAMIDE |
| JP2025525344A (ja) * | 2022-06-21 | 2025-08-05 | アストラゼネカ・アクチエボラーグ | Ｎ－（２－（４－シアノチアゾリジン－３－イル）－２－オキソエチル）－キノリン－４－カルボキサミド |
| CN121752300A (zh) | 2023-08-31 | 2026-03-27 | 荷兰拉德堡德大学学术医学中心 | 子宫内膜异位症示踪剂 |
| CN118955616B (zh) * | 2024-05-01 | 2025-09-02 | 杭州景嘉航生物医药科技有限公司 | 一种靶向结合成纤维细胞活化蛋白化合物及应用 |
| WO2026007968A1 (zh) * | 2024-07-01 | 2026-01-08 | 杭州景嘉航生物医药科技有限公司 | 一种靶向结合成纤维细胞活化蛋白的化合物及应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3017929A (en) * | 1959-01-07 | 1962-01-23 | Beloit Iron Works | Head box with balanced slice body |
| CA1309805C (en) | 1985-04-16 | 1992-11-03 | Naoki Higuchi | Dipeptide derivative and synthesis and use thereof |
| CA1320734C (en) * | 1986-02-04 | 1993-07-27 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same |
| JPH0774193B2 (ja) | 1986-07-29 | 1995-08-09 | サントリー株式会社 | ジペプチド誘導体及びその製法並びに用途 |
| ES2103287T3 (es) | 1987-02-23 | 1997-09-16 | Ono Pharmaceutical Co | Nuevos derivados de tiazolidina. |
| CA2004028C (en) * | 1988-12-08 | 1998-09-22 | Motoki Torizuka | Condensed benzene derivative |
| WO1990012005A1 (fr) * | 1989-04-13 | 1990-10-18 | Japan Tobacco Inc. | Nouveaux derives aminoacides possedant une activite d'inhibiteur de la prolylendopeptidase |
| US5462928A (en) * | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
| WO1991018877A1 (en) * | 1990-06-07 | 1991-12-12 | Zeria Pharmaceutical Co., Ltd. | Novel arylalkanoylamine derivative and drug containing the same |
| FR2681864B1 (fr) * | 1991-09-27 | 1995-03-31 | Adir | Nouveaux derives bicycliques azotes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| EP0641204B1 (en) * | 1992-05-20 | 2000-08-16 | Merck & Co. Inc. | 17-ethers and thioethers of 4-aza-steroids |
| US5536737A (en) * | 1992-11-20 | 1996-07-16 | Japan Tobacco Inc. | Compound having prolyl endopeptidase inhibitory activity and pharmaceutical use thereof |
| JP3810097B2 (ja) * | 1993-01-15 | 2006-08-16 | 明治製菓株式会社 | ピロリジン−２−イルカルボニル複素環式化合物誘導体 |
| EP0709373B1 (en) | 1993-07-23 | 2001-10-17 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Pyrrolidine derivative |
| JPH07126229A (ja) * | 1993-11-02 | 1995-05-16 | Yoshitomi Pharmaceut Ind Ltd | ジアリールケトン化合物およびその医薬用途 |
| PL322706A1 (en) | 1993-11-09 | 1998-02-16 | Merck & Co Inc | Piperidines, pyrolidines and hexahydro-1h-azepins enhancing growth hormone liberation |
| US5494919A (en) * | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| JPH07228529A (ja) * | 1994-02-17 | 1995-08-29 | Zeria Pharmaceut Co Ltd | コリンエステラーゼ賦活剤 |
| US5574017A (en) * | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
| US6017887A (en) | 1995-01-06 | 2000-01-25 | Sibia Neurosciences, Inc. | Peptide, peptide analog and amino acid analog protease inhibitors |
| EP1134213B1 (en) * | 1995-06-06 | 2005-11-02 | Pfizer Inc. | Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides |
| EP1104293A1 (en) * | 1998-08-21 | 2001-06-06 | Point Therapeutics, Inc. | Regulation of substrate activity |
| CN1362947A (zh) | 1999-03-15 | 2002-08-07 | Axys药物公司 | 用作蛋白酶抑制剂的n－氰基甲基酰胺 |
| EP1228061A4 (en) * | 1999-11-12 | 2004-12-15 | Guilford Pharm Inc | DIPEPTIDYL PEPTIDASE IV INHIBITORS; METHODS OF MANUFACTURE AND USE OF SAID INHIBITORS |
| GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| AU2001228309A1 (en) | 2000-01-24 | 2001-08-07 | Novo-Nordisk A/S | N-substituted 2-cyanopyroles and -pyrrolines which are inhibitors of the enzyme dpp-iv |
| GB0010188D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| US7138397B2 (en) | 2000-10-06 | 2006-11-21 | Tanabe Seiyaku Co., Ltd. | Nitrogenous 5-membered ring compounds |
| JP2004532838A (ja) | 2001-03-02 | 2004-10-28 | ブリストル−マイヤーズ スクイブ カンパニー | メラノコルチン受容体のモデュレーターとして有用な化合物及びそれを含む製薬組成物 |
| FR2822826B1 (fr) | 2001-03-28 | 2003-05-09 | Servier Lab | Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| CA2418543A1 (en) * | 2001-06-27 | 2003-01-09 | Probiodrug Ag | New dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents |
| FI20011466A0 (fi) * | 2001-07-04 | 2001-07-04 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö |
| EP1492525A2 (en) * | 2001-08-16 | 2005-01-05 | Probiodrug AG | Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
| BR0308816A (pt) * | 2002-04-08 | 2005-03-22 | Torrent Pharmaceuticals Ltd | Tiazolidina-4-carbonitrilas e análogos e seus usos como inibidores da dipeptil-peptidas |
| AU2003228793B2 (en) * | 2002-04-30 | 2008-01-03 | Trustees Of Tufts College | Smart Pro-Drugs of Serine Protease Inhibitors |
| US20050084490A1 (en) | 2002-07-09 | 2005-04-21 | Point Therapeutics, Inc. | Boroproline compound combination therapy |
| WO2004020434A1 (ja) * | 2002-08-30 | 2004-03-11 | Eisai Co., Ltd. | 含窒素芳香環誘導体 |
| KR20080030079A (ko) * | 2005-07-05 | 2008-04-03 | 트러스티즈 오브 터프츠 칼리지 | 섬유아세포 활성 단백질 알파의 억제제 |
-
2005
- 2005-09-02 EP EP05108049A patent/EP1760076A1/en not_active Withdrawn
-
2006
- 2006-08-31 KR KR1020087007975A patent/KR20080043383A/ko not_active Withdrawn
- 2006-08-31 US US11/991,286 patent/US8183280B2/en not_active Expired - Fee Related
- 2006-08-31 WO PCT/IB2006/003512 patent/WO2007085895A2/en not_active Ceased
- 2006-08-31 AU AU2006336854A patent/AU2006336854A1/en not_active Abandoned
- 2006-08-31 JP JP2008528601A patent/JP2009507011A/ja active Pending
- 2006-08-31 EP EP06849433A patent/EP1919864A2/en not_active Withdrawn
- 2006-08-31 RU RU2008112683/04A patent/RU2008112683A/ru not_active Application Discontinuation
- 2006-08-31 CA CA002627607A patent/CA2627607A1/en not_active Abandoned
-
2008
- 2008-04-01 ZA ZA200802867A patent/ZA200802867B/xx unknown
- 2008-04-02 NO NO20081636A patent/NO20081636L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009507011A5 (https=) | ||
| RU2008112683A (ru) | Ингибиторы fap | |
| RU2517345C2 (ru) | Способ лечения поликистозных заболеваний почек с помощью производных церамида | |
| JP2004523581A5 (https=) | ||
| CA2401502A1 (en) | Carboxylic acid derivatives as ip antagonists | |
| RU95112537A (ru) | Терапевтические гетероциклические соединения, способ их получения, фармацевтическая композиция, способ ее получения | |
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| JP2023541522A (ja) | 低分子量タンパク質分解物質及びその適用 | |
| RU2013138569A (ru) | Антагонисты рецептора минералокортикоидов | |
| JP2007502265A5 (https=) | ||
| RU2000131184A (ru) | Соединения, обладающие свойствами, способствующими выделению гормона роста | |
| JP2010533131A5 (https=) | ||
| RU2008120850A (ru) | Соединения и композиции в качестве ингибиторов протеинкиназ | |
| RU2007147344A (ru) | Новые производные 2-азетидинона для лечения гиперлипидемических заболеваний | |
| JP2006501306A5 (https=) | ||
| JP2006512321A5 (https=) | ||
| JP2015534567A5 (https=) | ||
| JP2011500537A5 (https=) | ||
| JP2007513988A5 (https=) | ||
| RU2006125509A (ru) | Полиниларилацетамиды | |
| RU2022100101A (ru) | Способы, композиции и наборы комбинированной терапии | |
| JP2020510655A5 (https=) | ||
| JP2005526745A5 (https=) | ||
| HK1144394B (en) | Method of treating polycystic kidney diseases with ceramide derivatives | |
| JP2003026569A (ja) | 肝疾患治療剤 |